Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PCRX logo PCRX
Upturn stock ratingUpturn stock rating
PCRX logo

Pacira BioSciences, Inc. (PCRX)

Upturn stock ratingUpturn stock rating
$24.99
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: PCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $30.6

1 Year Target Price $30.6

Analysts Price Target For last 52 week
$30.6 Target price
52w Low $12.61
Current$24.99
52w High $27.64

Analysis of Past Performance

Type Stock
Historic Profit -0.05%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.11B USD
Price to earnings Ratio -
1Y Target Price 30.6
Price to earnings Ratio -
1Y Target Price 30.6
Volume (30-day avg) 6
Beta 0.48
52 Weeks Range 12.61 - 27.64
Updated Date 08/15/2025
52 Weeks Range 12.61 - 27.64
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.75

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate 0.7171
Actual 0.74

Profitability

Profit Margin -18.06%
Operating Margin (TTM) 5.04%

Management Effectiveness

Return on Assets (TTM) 2.69%
Return on Equity (TTM) -15.57%

Valuation

Trailing PE -
Forward PE 8.83
Enterprise Value 1308407697
Price to Sales(TTM) 1.58
Enterprise Value 1308407697
Price to Sales(TTM) 1.58
Enterprise Value to Revenue 1.85
Enterprise Value to EBITDA 48
Shares Outstanding 44932700
Shares Floating 42194970
Shares Outstanding 44932700
Shares Floating 42194970
Percent Insiders 1.82
Percent Institutions 116.28

ai summary icon Upturn AI SWOT

Pacira BioSciences, Inc.

stock logo

Company Overview

overview logo History and Background

Pacira BioSciences, Inc. was founded in 2006. It focuses on developing, commercializing and manufacturing non-opioid pain management and regenerative health solutions.

business area logo Core Business Areas

  • Pain Management: The core business revolves around non-opioid pain management, primarily through EXPAREL, their flagship product. This segment also includes Iovera and ZILRETTA products used in human therapeutic applications.

leadership logo Leadership and Structure

Pacira is led by Frank D. Lee as Chief Executive Officer. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, finance, and administration. The board of directors provides oversight.

Top Products and Market Share

overview logo Key Offerings

  • EXPAREL (bupivacaine liposome injectable suspension): EXPAREL is a long-acting, local analgesic indicated for single-dose infiltration to produce postsurgical analgesia and as an interscalene brachial plexus nerve block to produce postsurgical analgesia. Main competitors include generic local anesthetics and opioid-based pain management solutions. Estimated that EXPAREL has about 20-30% market share in the long-acting local anesthetic segment. Revenue from EXPAREL contributes the majority of Pacira's total revenue.
  • Iovera System: Iovera is a handheld cryoanalgesia device that delivers focused cold therapy to targeted nerves, providing immediate pain relief without opioids. Competitors include nerve blocks and other non-opioid and opioid pain treatments. The exact market share is not publicly available, but it's smaller than EXPAREL.
  • ZILRETTA (triamcinolone acetonide extended-release injectable suspension): ZILRETTA, an injectable medicine, is used for adults to manage moderate to severe osteoarthritis (OA) knee pain. Competitors include other injectable and non-injectable corticosteroids and hyaluronic acid viscosupplements.

Market Dynamics

industry overview logo Industry Overview

The pain management market is growing due to the aging population, increasing surgical procedures, and rising awareness of non-opioid pain management options. There's a strong push for alternatives to opioids due to the opioid crisis.

Positioning

Pacira is positioned as a leader in the non-opioid pain management space, primarily through its innovative EXPAREL product. They are well positioned to capitalize on the growing demand for opioid alternatives.

Total Addressable Market (TAM)

The global pain management market is estimated to be over $80 billion. Pacira's focus on non-opioid solutions gives them access to a significant portion of this TAM, particularly the surgical and osteoarthritis pain segments.

Upturn SWOT Analysis

Strengths

  • Proprietary drug delivery technology (EXPAREL)
  • Strong market position in non-opioid pain management
  • Growing demand for opioid alternatives
  • Established sales and marketing infrastructure
  • Expanding product portfolio

Weaknesses

  • Reliance on EXPAREL for revenue
  • Patent expiry risks for EXPAREL
  • Competition from generic local anesthetics
  • Regulatory and reimbursement challenges

Opportunities

  • Expanding indications for EXPAREL
  • Acquiring or licensing new products
  • Penetrating new geographic markets
  • Partnering with hospitals and surgery centers

Threats

  • Generic competition for EXPAREL
  • Pricing pressures from payers
  • Changes in regulatory landscape
  • Development of competing non-opioid pain management technologies
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • BAX
  • ITCI
  • HGEN

Competitive Landscape

Pacira holds an advantage in the non-opioid postsurgical pain market with EXPAREL's sustained release formulation. Baxter offers a broader portfolio of products. ITCI and HGEN are key innovators in the space, but generally, EXPAREL has a market leadership position, though competition is growing.

Major Acquisitions

Flexion Therapeutics

  • Year: 2021
  • Acquisition Price (USD millions): 441
  • Strategic Rationale: Expanded Pacira's portfolio with ZILRETTA, a non-opioid treatment for osteoarthritis knee pain.

Growth Trajectory and Initiatives

Historical Growth: Pacira has experienced strong growth over the past decade, driven by the commercial success of EXPAREL and strategic acquisitions.

Future Projections: Analysts project continued growth for Pacira, driven by increasing demand for non-opioid pain management solutions and expansion of EXPAREL's indications. Revenue is expected to continue to increase, with EPS to follow.

Recent Initiatives: Recent initiatives include expanding the indications of EXPAREL, exploring new partnerships, and focusing on acquisitions.

Summary

Pacira BioSciences is a strong company in the non-opioid pain management space, particularly with EXPAREL. They are well-positioned to benefit from the shift away from opioids. Key areas to watch are generic competition for EXPAREL and the successful integration of acquired products, as well as economic impacts on surgery rates.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Research Reports
  • SEC Filings

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. Market share data are estimates. Financial data provided are approximates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pacira BioSciences, Inc.

Exchange NASDAQ
Headquaters Tampa, FL, United States
IPO Launch date 2011-02-03
CEO & Director Mr. Frank D. Lee
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 788
Full time employees 788

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.